Anti-Parainfluenza Virus Type 3 p69 polyclonal antibody

The human respiratory system is the primary site of infection for the human parainfluenza virus type 3 (Parainfluenzavirus-3, PIV3), an RNA virus belonging to the genus and family Paramyxoviridae. The most common kind of human parainfluenza virus is PIV3, which is known to cause severe respiratory infections, particularly in young children, the elderly, and those with weakened immune systems. The outer coat of PIV3, an enveloped virus, is made from the membrane of the host cell. Hemagglutinin-neuraminidase (HN) and fusion protein (F), two significant surface glycoproteins, are present.These glycoproteins regulate the virus's ability to cling to and enter host cells. The F protein is essential for the fusion of the viral envelope with the host cell membrane, which permits the viral nucleocapsid to enter the host cell, whereas the HN protein attaches to sialic acid receptors on the host cell surface to promote viral attachment. The N, P, M, F, HN, and L proteins are sequentially encoded by six genes that make up the roughly 15 kb single-stranded, negative-sense RNA genome of PIV3. The L protein is the main viral RNA polymerase, the M protein mediates virus assembly, the P protein is a component of the RNA-dependent RNA polymerase complex, and the N protein wraps the RNA to create the nucleocapsid. These gene products work together to control transcription, assembly, and viral replication. PIV3 usually enters the body through the nasal or pharyngeal mucosa and is transmitted by aerosols or direct touch. The HN protein initiates viral entry during infection by identifying and attaching to sialic acid receptors on the surface of the host cell. In order to release the viral nucleocapsid into the cytoplasm, the F protein helps the viral envelope fuse with the host cell membrane. The negative-strand RNA is copied into positive-strand templates inside the cytoplasm by PIV3's RNA-dependent RNA polymerase. These templates are subsequently utilized for transcription, which creates viral proteins to put together fresh virions for release. The glycosylation changes on PIV3's F and HN proteins contribute to its ability to evade the immune system. Antigenic epitopes may get obscured by these alterations, making it more difficult for the host immune system to recognize the virus. Additionally, PIV3 can avoid the host's innate immune response by preventing the production of interferon. The P protein increases the virus's capacity to reproduce and spread within host cells by preventing the phosphorylation of signal transducers and activators of transcription (STAT), which in turn blocks the interferon-mediated antiviral signaling cascade.

Symptoms of a PIV3 infection typically include fever, coughing, runny nose, and congestion in the upper respiratory tract. However, PIV3 infections can progress to more serious lower respiratory tract conditions such bronchitis, pneumonia, and acute laryngotracheobronchitis (croup) in newborns and immunocompromised people. Together with respiratory syncytial virus (RSV), PIV3 is a major cause of acute bronchiolitis and pneumonia in babies and frequently results in hospitalization for these conditions. PIV3 infections rise in the spring and early summer, following a seasonal trend. The virus is extremely contagious and can quickly spread to crowded areas, including homes, kindergartens, and daycare facilities. Although PIV3 infection induces an immune response, it does not confer lasting immunity, making reinfection in both children and adults fairly common. The diagnosis of PIV3 infection relies heavily on laboratory tests, as its clinical symptoms are difficult to distinguish from other respiratory viral infections like influenza and RSV. Common diagnostic methods include viral culture, antigen detection, reverse transcription polymerase chain reaction (RT-PCR), and serological testing. RT-PCR, with its high sensitivity and specificity, has become widely used for diagnosing PIV3 infections in clinical settings. Virus isolation is typically performed using human embryonic kidney or monkey kidney cell lines, but this method is time-consuming and requires specialized laboratory conditions. Antigen detection, which uses antibodies specific to PIV3 proteins in rapid immunoassays, can provide a quick diagnosis, though it has lower sensitivity and a higher likelihood of false negatives.

As of right now, PIV3 infections cannot be treated with any particular antiviral medication. Supportive care is the primary treatment for symptoms; in more severe cases, oxygen therapy, mechanical ventilation, or critical care support may be necessary, particularly in older patients and newborns with underlying illnesses. Preventing PIV3 infection requires maintaining good hygiene, which includes frequent hand washing, avoiding sick persons, and limiting exposure in busy areas during peak seasons. Despite advancements in PIV3 vaccine development, no vaccine has received widespread approval for clinical usage as of yet. To achieve successful immunization against PIV3, researchers are investigating innovative viral vector vaccines, live attenuated vaccines, and inactivated vaccines. In summary, human parainfluenza virus type 3 is a key pathogen responsible for respiratory infections in infants, particularly in lower respiratory tract infections, where its role cannot be overlooked. While infections are generally self-limiting, PIV3 can lead to serious consequences in certain populations, presenting challenges in clinical diagnosis and treatment. With the advancement of molecular biology techniques, diagnostic methods for PIV3 are improving, but specific antiviral therapies and effective vaccines remain areas for further exploration. Future research may focus on understanding immune mechanisms, developing vaccines, and designing novel antiviral therapies to reduce the social and economic burdens of PIV3 infections.

Anti-PIV-3 antibody
Anti-parainfluenza virus type 3 antibody
PIV-3 p69 antibody